LONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE
Preprint
Abstract
Background: To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on ovarian reserve by serum anti-Mullerian hormone (AMH) levels in women with breast cancer. Methods: One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate+5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI. Results: Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p<0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p=0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery. Conclusions: Both AC-based and CMF regimens significantly compromise ovarian reserve, which does not recover during the 12-24-month post-chemotherapy follow up. In contrast, tamoxifen treatment does not seem to alter ovarian reserve. This novel information should be valuable for fertility preservation counselling and in assessing future reproductive potential of breast cancer survivors.Keywords
This publication has 38 references indexed in Scilit:
- Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiencyFertility and Sterility, 2020
- BRCA-related ATM-mediated DNA double-strand break repair and ovarian agingHuman Reproduction Update, 2019
- Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical ImpactFuture Oncology, 2016
- Assessing ovarian response: antral follicle count versus anti-Müllerian hormoneReproductive BioMedicine Online, 2015
- Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in womenMaturitas, 2015
- Correlation of ovarian reserve tests with histologically determined primordial follicle numberFertility and Sterility, 2011
- Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populationsAnnals of Oncology, 2008
- Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal functionCancer, 2007
- The Rates of Chemotherapy-Induced Amenorrhea in Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Followed by a TaxaneAmerican Journal of Clinical Oncology, 2007
- Regulation of ovarian function: the role of anti-Mullerian hormoneReproduction, 2002